{'fraction_non_alphanumeric': 0.025029103608847497, 'fraction_numerical': 0.00989522700814901, 'mean_word_length': 5.183453237410072, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Energy Expenditure in Patients with Cancer Influence of Whole Body Protein Turnover Rate on Resting Updated

Whole body protein turnover and resting energy expenditure are measured simultaneously in weight stable and weight losing patients with lung (n = 22) or colorectal cancer (n = 38). These results were compared with those from weight stable and weight losing non-cancer controls (n = 22). Rates of whole body protein turnover were calculated from the plateau isotopie enrichment of urinary ammonia and urea following a primed, continuous, 24-h infusion of |lsN|glycine. Resting energy expend iture was measured by indirei calorimetry. All groups of cancer patients had significantly elevated rates of whole body protein turnover (P < 0.05) and synthesized, on average, 1.9 g/kg/ day more protein compared with weight stable non-cancer controls. In contrast, the resting energy expenditure of cancer patients and controls was similar. Moreover, there was no correlation between individual rates of whole body protein turnover. Thus, although cancer patients had rates of whole body protein turnover which were 50-70% greater than controls, this did not result in a measurable increase in resting energy expenditure. The assumption that elevation of whole body protein turnover or resting energy expenditure causes weight loss in cancer patients must be an oversimplification. An acute phase protein response was observed in the majority of cancer patients. Although the presence of such an inflammatory response did not correlate with the rate of whole body protein turnover, the role of inflammatory mediators in the pathogenesis of disturbed protein metab olism in cancer patients merits further investigation.